November 19, 2025 a 07:43 am
BDX: Fundamental Ratio Analysis - Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) demonstrates a stable financial performance with resilience in the healthcare sector. The company's diverse product segments and global reach provide a solid foundation for consistent revenue streams. However, potential risks include fluctuations in regulatory policies and market competition.
Fundamental Rating
The company's current overall score stands at 3 out of 5, indicating a strong performance in certain areas with room for improvement in others.
| Category | Score | |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 3 |
Historical Rating
Analyzing historical ratings reveals the company's consistent performance with slight fluctuations over the recent period.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-18 | 3 | 5 | 3 | 5 | 1 | 1 | 3 |
| Earlier | 0 | 5 | 3 | 5 | 1 | 1 | 3 |
Analyst Price Targets
Analysts provide a median target price of $280, with a consensus of $283.73, indicating a generally favorable outlook.
| High | Low | Median | Consensus |
|---|---|---|---|
| $312 | $260 | $280 | $283.73 |
Analyst Sentiment
The sentiment amongst analysts is predominantly 'Buy', suggesting positive expectations for BDX's future performance.
| Recommendation | Count | |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 16 | |
| Hold | 16 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Becton, Dickinson and Company presents a balanced investment opportunity with strong product offerings and an impressive global footprint. While its financial metrics suggest stability, attention should be directed toward debt management and competitive pressures. Analysts remain optimistic about BDX's prospects, supported by reliable earnings and innovation within the healthcare space.